##### 



Exhibit
10.52   ***Text Omitted and Filed SeparatelyConfidential Treatment
RequestedUnder 17 C.F.R. §§ 200.80(b)(4)
and240.24b-2(b)(1)
 LICENSE AGREEMENT
 IDM Pharmexa Party Parties
  Asset Purchase Agreement
  ®
 ®
  ARTICLE 1 CERTAIN DEFINITIONS
  Affiliate
 Breach
 Cancer
 Confidential Information




---



##### 



®
 Effective Date
 Field ® Schedule A ® Schedule A
 IDM Cancer Product
 Indemnitee
 Indemnitor
 Invention
 Licensed Know-How
 Licensed Patents ®
 Licensed Technology
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)
 2




---



##### 



PADRE®
 Parties
 Party
 Patents
 Person
 Third Party
 ARTICLE 2 LICENSE GRANT
 Grant of License
 License




---



##### 



Rights Retained by Pharmexa
 Reasonable Access
 ARTICLE 3 CONSIDERATION FOR LICENSE
 Consideration
 ARTICLE 4 PATENTS
 No Assignment ®
 Patent Filing, Prosecution and Maintenance
    *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)
 4




---



##### 



Infringement Actions
   Inventions ® ( Inventions
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)




---



##### 



Infringement of Third Party Rights ® ®
 6




---



##### 



ARTICLE 5 CONFIDENTIALITY
 Confidentiality ® ® ®
 Exceptions Article 5
 Disclosure Required by Law
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)




---



##### 



Return of Confidential Information
 Injunctive Relief
 Disclosure of Agreement
 Scientific Publications ® ®
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)




---



##### 



ARTICLE 6 REPRESENTATIONS AND WARRANTIES
 General Representations
 Authority
 Due Execution
 No Third Party Approval
 Binding Agreement
 Disclaimers
   ®
 9




---



##### 



ARTICLE 7 INDEMNIFICATION
 Indemnification
 IDM Indemnitee Losses
 Pharmexa Indemnitee
 Certain Procedures Regarding Indemnification
 Claim Claim Notice
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)
 10




---



##### 



Limitation on Liability
 Resolution of Disputed Indemnification Claim Contested Claim
 ARTICLE 8 TERM AND TERMINATION
 Term
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)




---



##### 



8.2
Termination
  provided however provided further
 Effect of Termination
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)




---



##### 



Remedy Not Exclusive
 Rights in Bankruptcy
 ARTICLE 9 DISPUTE RESOLUTION
 Arbitration
 Dispute
       *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)
 13




---



##### 



ARTICLE 10 MISCELLANEOUS
 Survival
 Force Majeure
 Entire Agreement
 Assignment provided however




---



##### 



New License
 Waivers
 Severance
 Notices
 If
to IDM:
    

If
to Pharmexa:IDM Pharma, Inc.
    
    Pharmexa, Inc.9 Parker, Suite 100
    
    5820 Nancy Ridge DriveIrvine, CA 92618-1605
    
    San Diego, CA 92121USA
    
    USAAttn: Jean-Loup Romet-Lemonne, M.D.
    
    Attn: Chief Executive OfficerWith a copy to:
    
    With copies to:Cooley Godward LLP
    
    Pharmexa A/S
 *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)
 15




---



##### 



4401 Eastgate Mall
    
    Kogle Allé 6San Diego, CA 92121-1909
    
    DK-2970 HørsholmUSA
    
    DenmarkAttn: Barbara L. Borden,Esq.
    
    Attn: Chief Financial OfficerandNordlicht & Hand645 Fifth AvenueNew York, NY 10022USAAttn: Brian M. Hand, Esq.
 Costs
 Article and Section Headings and Gender
 Counterparts
 Governing Law
 Mutual Drafting
 Schedules
  16




---



##### 



EXECUTION PAGE
PADRE ® LICENSE AGREEMENT
  IDM PHARMA, INC.
    
    
    
    PHARMEXA, INC.By:
 /s/ Robert De Vaere
    
    
    
    By:
 /s/ Marc HertzName:
    
    Robert De Vaere
    
    
    
    Name:
    
    Marc HertzTitle:
    
    Chief Financial Officer
    
    
    
    Title:
    
    CEO
 17




---



##### 



SCHEDULE A
 LICENSES AND OTHER AGREEMENTS
  *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)
 18




---



##### 



SCHEDULE B
 LICENSED PATENTS
  *Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)




---



##### 



*Confidential Treatment Requested   under
17 C.F.R. §§ 200.80(b)(4) and   240.24b-2(b)(1)